CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis.

Cancers (Basel) · 2023 · PMC10340287 · PMID 37444496

Europe PMC DOI

hedged sentences

0.0301

closest p · 0.6× alpha

0.0301

boldest claim

The sentences

did not reach statistical significancep = 0.0301actually significant

Even though the interim OS results of MONARCH-3 did not reach statistical significance (HR = 0.754, 95% CI 0.584–0.974, p = 0.0301), its absolute value is also very impressive, reaching 67.1 months.

also in 20,614 other papers

a clear trendno p-value reported

Between the Ribo + NSAI and placebo + NSAI groups, there was no substantial difference in the PFS, but a clear trend was shown (HR 0.79, 95% CI 0.58–1.06).

also in 4,369 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.